Paliperidone Palmitate
(VOMKSBFLAZZBOW-UHFFFAOYSA-N)
Structure
- SMILES
- CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(c2=O)CCN1CCC(CC1)c1noc2c1ccc(c2)F
- Molecular Formula:
- C39H57FN4O4
- Molecular Weight:
- 664.893
- Log P:
- 9.0514
- Hydrogen Bond Acceptor:
- 8
- Hydrogen Bond Donor:
- 0
- TPSA:
- 90.46
- CAS Number(s):
- 199739-10-1
Synonym(s)
1.
Paliperidone Palmitate
2.
3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3.
9-Hydroxy-risperidone
4.
9-Hydroxyrisperidone
5.
9-OH-risperidone
6.
Invega
7.
Invega Sustenna
8.
Paliperidone
9.
R 76477
10.
R-76477
11.
9 Hydroxy risperidone
12.
9 Hydroxyrisperidone
13.
9 OH risperidone
14.
Palmitate, Paliperidone
15.
R76477
16.
Sustenna, Invega
External Link(s)
| MeSH | D000068882 |
| PubChem Compound | 9852746 |
| ChEBI | 83808 |
| CHEMBL | CHEMBL2107360 |
| DrugCentral | 4498 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 222 Canada Vigilance: 9 | Canada Vigilance US FAERS | |
| 2 | Schizophrenia | FAERS: 118 Canada Vigilance: 15 | CTD Canada Vigilance US FAERS | |
| 3 | Drug dose omission | FAERS: 89 | US FAERS | |
| 4 | Inappropriate schedule of drug administration | FAERS: 74 | US FAERS | |
| 5 | Delirium | FAERS: 60 | US FAERS | |
| 6 | Anxiety | FAERS: 54 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 7 | Malaise | FAERS: 53 | US FAERS | |
| 8 | Incorrect dose administered | FAERS: 48 Canada Vigilance: 9 | Canada Vigilance US FAERS | |
| 9 | Product use in unapproved indication | FAERS: 48 Canada Vigilance: 11 | Canada Vigilance US FAERS | |
| 10 | Injection site pain | FAERS: 47 | US FAERS | |
| 11 | Paranoia | FAERS: 46 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Agitation | FAERS: 45 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 13 | Blood prolactin increased | FAERS: 43 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 14 | Product use issue | FAERS: 42 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 15 | Akathisia | FAERS: 38 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 16 | Pulmonary Embolism | FAERS: 37 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 17 | Psychotic symptom | FAERS: 34 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 18 | Dizziness | FAERS: 31 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 19 | Fatigue | FAERS: 30 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 20 | Completed Suicide | FAERS: 29 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 21 | Syringe issue | FAERS: 28 | US FAERS | |
| 22 | Tremor | FAERS: 28 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 23 | Diabetes Mellitus | FAERS: 27 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 24 | Weight decreased | FAERS: 27 | US FAERS | |
| 25 | Feeling abnormal | FAERS: 26 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 26 | Injection site nodule | FAERS: 26 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 27 | Suicide attempt | FAERS: 26 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 28 | Wrong technique in product usage process | FAERS: 26 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 29 | Adverse event | FAERS: 25 | US FAERS | |
| 30 | Nausea | FAERS: 24 | US FAERS | |
| 31 | Headache | FAERS: 23 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 32 | Product dose omission | FAERS: 23 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 33 | Injection site mass | FAERS: 21 | US FAERS | |
| 34 | Needle issue | FAERS: 20 | US FAERS | |
| 35 | Overdose | FAERS: 20 | US FAERS | |
| 36 | Asthenia | FAERS: 19 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 37 | Device malfunction | FAERS: 19 | US FAERS | |
| 38 | Restlessness | FAERS: 19 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 39 | Accidental exposure to product | FAERS: 18 | US FAERS | |
| 40 | Catatonia | FAERS: 17 | US FAERS | |
| 41 | Pneumonia | FAERS: 17 | US FAERS | |
| 42 | Vomiting | FAERS: 17 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 43 | Rhabdomyolysis | FAERS: 16 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 44 | Drug effect incomplete | FAERS: 15 | US FAERS | |
| 45 | Injection site abscess | FAERS: 15 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 46 | Musculoskeletal stiffness | FAERS: 15 | US FAERS | |
| 47 | Neuroleptic Malignant Syndrome | FAERS: 15 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 48 | Psychiatric decompensation | FAERS: 15 | US FAERS | |
| 49 | Psychiatric symptom | FAERS: 15 | US FAERS | |
| 50 | Sexual Dysfunction | FAERS: 15 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 51 | Blood creatine phosphokinase increased | FAERS: 14 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 52 | Product leakage | FAERS: 14 | US FAERS | |
| 53 | Erectile dysfunction | FAERS: 13 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 54 | Pain | FAERS: 13 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 55 | Drug administration error | FAERS: 12 | US FAERS | |
| 56 | Dystonia | FAERS: 12 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 57 | Hypotension | FAERS: 12 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 58 | Somnolence | FAERS: 12 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 59 | Tachycardia | FAERS: 12 | US FAERS | |
| 60 | Tardive Dyskinesia | FAERS: 12 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 61 | Cardiac Arrest | FAERS: 11 | US FAERS | |
| 62 | Drooling | FAERS: 11 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 63 | Epilepsy | FAERS: 11 | US FAERS | |
| 64 | Inappropriate schedule of product administration | FAERS: 11 Canada Vigilance: 22 | Canada Vigilance US FAERS | |
| 65 | Injection Site Reaction | FAERS: 11 | US FAERS | |
| 66 | Mental impairment | FAERS: 11 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 67 | Amnesia | FAERS: 10 | US FAERS | |
| 68 | Deep Vein Thrombosis | FAERS: 10 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 69 | Drug abuse | FAERS: 10 | US FAERS | |
| 70 | General physical health deterioration | FAERS: 10 | US FAERS | |
| 71 | Incorrect route of drug administration | FAERS: 10 | US FAERS | |
| 72 | Myalgia | FAERS: 10 | US FAERS | |
| 73 | Dissociation | FAERS: 9 | US FAERS | |
| 74 | Injection site erythema | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 75 | Muscle Rigidity | FAERS: 9 | US FAERS | |
| 76 | Myocardial Infarction | FAERS: 9 | US FAERS | |
| 77 | Schizoaffective Disorder | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 78 | Thrombosis | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 79 | Alopecia | FAERS: 8 | US FAERS | |
| 80 | Anger | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 81 | Injection site extravasation | FAERS: 8 | US FAERS | |
| 82 | Palpitations | FAERS: 8 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 83 | Altered state of consciousness | FAERS: 7 | US FAERS | |
| 84 | Apathy | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 85 | Complication associated with device | FAERS: 7 | US FAERS | |
| 86 | Depressed mood | FAERS: 7 | US FAERS | |
| 87 | Drug administered at inappropriate site | FAERS: 7 | US FAERS | |
| 88 | Drug ineffective for unapproved indication | FAERS: 7 | US FAERS | |
| 89 | Drug prescribing error | FAERS: 7 | US FAERS | |
| 90 | Erythema | FAERS: 7 | US FAERS | |
| 91 | Intentional self-injury | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 92 | Lethargy | FAERS: 7 | US FAERS | |
| 93 | Mental status changes | FAERS: 7 | US FAERS | |
| 94 | Pruritus | FAERS: 7 | US FAERS | |
| 95 | Syncope | FAERS: 7 | US FAERS | |
| 96 | Vertigo | FAERS: 7 | US FAERS | |
| 97 | Wrong drug administered | FAERS: 7 | US FAERS | |
| 98 | Aphasia | FAERS: 6 | US FAERS | |
| 99 | Bipolar Disorder | FAERS: 6 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 100 | Blood triglycerides increased | FAERS: 6 | US FAERS | |
| 101 | Dehydration | FAERS: 6 | US FAERS | |
| 102 | Depressed Level of Consciousness | FAERS: 6 | US FAERS | |
| 103 | Disorientation | FAERS: 6 | US FAERS | |
| 104 | Dysarthria | FAERS: 6 | US FAERS | |
| 105 | Gamma-Glutamyltransferase Increased | FAERS: 6 | US FAERS | |
| 106 | Hypersensitivity | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 107 | Injection site cyst | FAERS: 6 | US FAERS | |
| 108 | Nasopharyngitis | FAERS: 6 | US FAERS | |
| 109 | Nervousness | FAERS: 6 | US FAERS | |
| 110 | Product quality issue | FAERS: 6 | US FAERS | |
| 111 | Psoriasis | FAERS: 6 | US FAERS | |
| 112 | Urinary Incontinence | FAERS: 6 | US FAERS | |
| 113 | Wrong technique in drug usage process | FAERS: 6 | US FAERS | |
| 114 | Alanine Aminotransferase Increased | FAERS: 5 | US FAERS | |
| 115 | Back Pain | FAERS: 5 | US FAERS | |
| 116 | Blunted affect | FAERS: 5 | US FAERS | |
| 117 | Cerebrovascular accident | FAERS: 5 | US FAERS | |
| 118 | Chest Pain | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 119 | Constipation | FAERS: 5 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 120 | Device leakage | FAERS: 5 | US FAERS | |
| 121 | Device occlusion | FAERS: 5 | US FAERS | |
| 122 | Drug level decreased | FAERS: 5 | US FAERS | |
| 123 | Emotional distress | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 124 | Epistaxis | FAERS: 5 | US FAERS | |
| 125 | Hypokinesia | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 126 | Incorrect product storage | FAERS: 5 | US FAERS | |
| 127 | Induration | FAERS: 5 | US FAERS | |
| 128 | Medication Error | FAERS: 5 | US FAERS | |
| 129 | Mood swings | FAERS: 5 | US FAERS | |
| 130 | Nonspecific reaction | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 131 | Peripheral swelling | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 132 | Polydipsia | FAERS: 5 | US FAERS | |
| 133 | Priapism | FAERS: 5 | US FAERS | |
| 134 | Pulmonary thrombosis | FAERS: 5 | US FAERS | |
| 135 | Sudden death | FAERS: 5 | US FAERS | |
| 136 | Therapeutic product effect decreased | FAERS: 5 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 137 | Therapy cessation | FAERS: 5 | US FAERS | |
| 138 | Urinary tract infection | FAERS: 5 | US FAERS | |
| 139 | Visual Impairment | FAERS: 5 | US FAERS | |
| 140 | White blood cell count decreased | FAERS: 5 | US FAERS | |
| 141 | Acute kidney injury | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 142 | Angina Pectoris | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 143 | Aspartate Aminotransferase Increased | FAERS: 4 | US FAERS | |
| 144 | Bedridden | FAERS: 4 | US FAERS | |
| 145 | Blood cholesterol increased | FAERS: 4 | US FAERS | |
| 146 | Blood glucose increased | FAERS: 4 | US FAERS | |
| 147 | Cystitis | FAERS: 4 | US FAERS | |
| 148 | Drug Dependence | FAERS: 4 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 149 | Drug abuser | FAERS: 4 | US FAERS | |
| 150 | Drug level increased | FAERS: 4 | US FAERS | |
| 151 | Dysuria | FAERS: 4 | US FAERS | |
| 152 | Euphoric mood | FAERS: 4 | US FAERS | |
| 153 | Flat affect | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 154 | Fracture | FAERS: 4 | US FAERS | |
| 155 | Glaucoma | FAERS: 4 | US FAERS | |
| 156 | Incoherent | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 157 | Incorrect dose administered by device | FAERS: 4 | US FAERS | |
| 158 | Injection site bruising | FAERS: 4 | US FAERS | |
| 159 | Intentional drug misuse | FAERS: 4 | US FAERS | |
| 160 | Liquid product physical issue | FAERS: 4 | US FAERS | |
| 161 | Memory impairment | FAERS: 4 | US FAERS | |
| 162 | Neutrophil count decreased | FAERS: 4 | US FAERS | |
| 163 | Pancreatitis | FAERS: 4 | US FAERS | |
| 164 | Procedural complication | FAERS: 4 | US FAERS | |
| 165 | Product formulation issue | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 166 | Staring | FAERS: 4 | US FAERS | |
| 167 | Subcutaneous Abscess | FAERS: 4 | US FAERS | |
| 168 | Swelling | FAERS: 4 | US FAERS | |
| 169 | Tinnitus | FAERS: 4 | US FAERS | |
| 170 | Transaminases increased | FAERS: 4 | US FAERS | |
| 171 | Water Intoxication | FAERS: 4 | US FAERS | |
| 172 | Abdominal Pain | FAERS: 3 | US FAERS | |
| 173 | Accidental overdose | FAERS: 3 | US FAERS | |
| 174 | Activities of daily living impaired | FAERS: 3 | US FAERS | |
| 175 | Acute psychosis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 176 | Anaphylactic shock | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 177 | Arthralgia | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 178 | Bradycardia | FAERS: 3 | US FAERS | |
| 179 | Bradyphrenia | FAERS: 3 | US FAERS | |
| 180 | Bronchitis | FAERS: 3 | US FAERS | |
| 181 | Chills | FAERS: 3 | US FAERS | |
| 182 | Dysgeusia | FAERS: 3 | US FAERS | |
| 183 | Dyspepsia | FAERS: 3 | US FAERS | |
| 184 | Elevated mood | FAERS: 3 | US FAERS | |
| 185 | Emotional disorder | FAERS: 3 | US FAERS | |
| 186 | Emotional poverty | FAERS: 3 | US FAERS | |
| 187 | Enuresis | FAERS: 3 | US FAERS | |
| 188 | Erysipelas | FAERS: 3 | US FAERS | |
| 189 | Eye pain | FAERS: 3 | US FAERS | |
| 190 | Head discomfort | FAERS: 3 | US FAERS | |
| 191 | Head titubation | FAERS: 3 | US FAERS | |
| 192 | Hepatitis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 193 | Hypermetabolism | FAERS: 3 | US FAERS | |
| 194 | Hypervigilance | FAERS: 3 | US FAERS | |
| 195 | Impaired work ability | FAERS: 3 | US FAERS | |
| 196 | Incorrect route of product administration | FAERS: 3 | US FAERS | |
| 197 | Infection | FAERS: 3 | US FAERS | |
| 198 | Inflammation | FAERS: 3 | US FAERS | |
| 199 | Initial insomnia | FAERS: 3 | US FAERS | |
| 200 | Injection site infection | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 201 | Injection site inflammation | FAERS: 3 | US FAERS | |
| 202 | Leukopenia | FAERS: 3 | US FAERS | |
| 203 | Libido disorder | FAERS: 3 | US FAERS | |
| 204 | Lip swelling | FAERS: 3 | US FAERS | |
| 205 | Loss of personal independence in daily activities | FAERS: 3 | US FAERS | |
| 206 | Lower respiratory tract infection | FAERS: 3 | US FAERS | |
| 207 | Mastitis | FAERS: 3 | US FAERS | |
| 208 | Monoplegia | FAERS: 3 | US FAERS | |
| 209 | Morbid thoughts | FAERS: 3 | US FAERS | |
| 210 | Muscle tightness | FAERS: 3 | US FAERS | |
| 211 | Neutropenia | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 212 | Oculogyric crisis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 213 | Oropharyngeal pain | FAERS: 3 | US FAERS | |
| 214 | Overweight | FAERS: 3 | US FAERS | |
| 215 | Pancytopenia | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 216 | Phlebitis | FAERS: 3 | US FAERS | |
| 217 | Product administration error | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 218 | Product physical consistency issue | FAERS: 3 | US FAERS | |
| 219 | Product physical issue | FAERS: 3 | US FAERS | |
| 220 | Respiratory Failure | FAERS: 3 | US FAERS | |
| 221 | Sepsis | FAERS: 3 | US FAERS | |
| 222 | Skin reaction | FAERS: 3 | US FAERS | |
| 223 | Sluggishness | FAERS: 3 | US FAERS | |
| 224 | Stress | FAERS: 3 | US FAERS | |
| 225 | Thrombocytopenia | FAERS: 3 | US FAERS | |
| 226 | Urinary Retention | FAERS: 3 | US FAERS | |
| 227 | treatment failure | FAERS: 3 | US FAERS | |
| 228 | Abasia | FAERS: 2 | US FAERS | |
| 229 | Abnormal weight gain | FAERS: 2 | US FAERS | |
| 230 | Abscess | FAERS: 2 | US FAERS | |
| 231 | Acne | FAERS: 2 | US FAERS | |
| 232 | Anhedonia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 233 | Application site erythema | FAERS: 2 | US FAERS | |
| 234 | Application site swelling | FAERS: 2 | US FAERS | |
| 235 | Ascites | FAERS: 2 | US FAERS | |
| 236 | Asthenopia | FAERS: 2 | US FAERS | |
| 237 | Asthma | FAERS: 2 | US FAERS | |
| 238 | Ataxia | FAERS: 2 | US FAERS | |
| 239 | Blindness | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 240 | Blood creatinine increased | FAERS: 2 | US FAERS | |
| 241 | Blood lactate dehydrogenase increased | FAERS: 2 | US FAERS | |
| 242 | Blood urine present | FAERS: 2 | US FAERS | |
| 243 | Bone pain | FAERS: 2 | US FAERS | |
| 244 | Burning sensation | FAERS: 2 | US FAERS | |
| 245 | Cerebral Infarction | FAERS: 2 | US FAERS | |
| 246 | Chest discomfort | FAERS: 2 | US FAERS | |
| 247 | Choking | FAERS: 2 | US FAERS | |
| 248 | Coronary Artery Disease | FAERS: 2 | US FAERS | |
| 249 | Deafness | FAERS: 2 | US FAERS | |
| 250 | Decreased eye contact | FAERS: 2 | US FAERS | |
| 251 | Delusional disorder, unspecified type | FAERS: 2 | US FAERS | |
| 252 | Dementia | FAERS: 2 | US FAERS | |
| 253 | Diabetes Insipidus | FAERS: 2 | US FAERS | |
| 254 | Discomfort | FAERS: 2 | US FAERS | |
| 255 | Disease Progression | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 256 | Disease recurrence | FAERS: 2 | US FAERS | |
| 257 | Drug screen positive | FAERS: 2 | US FAERS | |
| 258 | Dysphonia | FAERS: 2 | US FAERS | |
| 259 | Eczema | FAERS: 2 | US FAERS | |
| 260 | Expired product administered | FAERS: 2 | US FAERS | |
| 261 | Exposure to contaminated device | FAERS: 2 | US FAERS | |
| 262 | Facial paralysis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 263 | Flatulence | FAERS: 2 | US FAERS | |
| 264 | Formication | FAERS: 2 | US FAERS | |
| 265 | Gait inability | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 266 | Gaze palsy | FAERS: 2 | US FAERS | |
| 267 | General physical condition abnormal | FAERS: 2 | US FAERS | |
| 268 | Hallucinations, mixed | FAERS: 2 | US FAERS | |
| 269 | Hypersomnia | FAERS: 2 | US FAERS | |
| 270 | Hypertensive crisis | FAERS: 2 | US FAERS | |
| 271 | Hypomania | FAERS: 2 | US FAERS | |
| 272 | Hypometabolism | FAERS: 2 | US FAERS | |
| 273 | Hypoxia | FAERS: 2 | US FAERS | |
| 274 | Impaired self-care | FAERS: 2 | US FAERS | |
| 275 | Incorrect drug administration duration | FAERS: 2 | US FAERS | |
| 276 | Influenza | FAERS: 2 | US FAERS | |
| 277 | Injection site cellulitis | FAERS: 2 | US FAERS | |
| 278 | Injection site granuloma | FAERS: 2 | US FAERS | |
| 279 | Injection site pruritus | FAERS: 2 | US FAERS | |
| 280 | Injury associated with device | FAERS: 2 | US FAERS | |
| 281 | Joint stiffness | FAERS: 2 | US FAERS | |
| 282 | Joint swelling | FAERS: 2 | US FAERS | |
| 283 | Lack of spontaneous speech | FAERS: 2 | US FAERS | |
| 284 | Leukocytosis | FAERS: 2 | US FAERS | |
| 285 | Lymphoma | FAERS: 2 | US FAERS | |
| 286 | Medication residue present | FAERS: 2 | US FAERS | |
| 287 | Menopause | FAERS: 2 | US FAERS | |
| 288 | Metabolic acidosis | FAERS: 2 | US FAERS | |
| 289 | Middle insomnia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 290 | Multiple Sclerosis | FAERS: 2 | US FAERS | |
| 291 | Musculoskeletal Pain | FAERS: 2 | US FAERS | |
| 292 | Nodule | FAERS: 2 | US FAERS | |
| 293 | Obesity | FAERS: 2 | US FAERS | |
| 294 | Onychomycosis | FAERS: 2 | US FAERS | |
| 295 | Pancreatic carcinoma | FAERS: 2 | US FAERS | |
| 296 | Physical disability | FAERS: 2 | US FAERS | |
| 297 | Polyuria | FAERS: 2 | US FAERS | |
| 298 | Poor peripheral circulation | FAERS: 2 | US FAERS | |
| 299 | Poor personal hygiene | FAERS: 2 | US FAERS | |
| 300 | Poor quality sleep | FAERS: 2 | US FAERS | |
| 301 | Post procedural complication | FAERS: 2 | US FAERS | |
| 302 | Post-injection delirium sedation syndrome | FAERS: 2 | US FAERS | |
| 303 | Prescribed overdose | FAERS: 2 | US FAERS | |
| 304 | Product deposit | FAERS: 2 | US FAERS | |
| 305 | Product storage error | FAERS: 2 | US FAERS | |
| 306 | Prolactinoma | FAERS: 2 | US FAERS | |
| 307 | Psychomotor skills impaired | FAERS: 2 | US FAERS | |
| 308 | Reaction to drug excipients | FAERS: 2 | US FAERS | |
| 309 | Respiratory distress | FAERS: 2 | US FAERS | |
| 310 | Restless Legs Syndrome | FAERS: 2 | US FAERS | |
| 311 | Retrograde ejaculation | FAERS: 2 | US FAERS | |
| 312 | Sinus Tachycardia | FAERS: 2 | US FAERS | |
| 313 | Slow speech | FAERS: 2 | US FAERS | |
| 314 | Somnambulism | FAERS: 2 | US FAERS | |
| 315 | Stupor | FAERS: 2 | US FAERS | |
| 316 | Tension | FAERS: 2 | US FAERS | |
| 317 | Therapeutic product effect incomplete | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 318 | Thirst | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 319 | Toxicity to various agents | FAERS: 2 | US FAERS | |
| 320 | Trismus | FAERS: 2 | US FAERS | |
| 321 | Unevaluable event | FAERS: 2 | US FAERS | |
| 322 | Urticaria | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 323 | Vascular pain | FAERS: 2 | US FAERS | |
| 324 | Venous Thrombosis | FAERS: 2 | US FAERS | |
| 325 | Wrong product administered | FAERS: 2 | US FAERS | |
| 326 | intensive care | FAERS: 2 | US FAERS | |
| 327 | jaundice | FAERS: 2 | US FAERS | |
| 328 | Abdominal discomfort | FAERS: 1 | US FAERS | |
| 329 | Abscess of eyelid | FAERS: 1 | US FAERS | |
| 330 | Abulia | FAERS: 1 | US FAERS | |
| 331 | Accidental underdose | FAERS: 1 | US FAERS | |
| 332 | Acne fulminans | FAERS: 1 | US FAERS | |
| 333 | Acute left ventricular failure | FAERS: 1 | US FAERS | |
| 334 | Alopecia Areata | FAERS: 1 | US FAERS | |
| 335 | Amimia | FAERS: 1 | US FAERS | |
| 336 | Amyotrophic Lateral Sclerosis | FAERS: 1 | US FAERS | |
| 337 | Anosognosia | FAERS: 1 | US FAERS | |
| 338 | Anticholinergic Syndrome | FAERS: 1 | US FAERS | |
| 339 | Antipsychotic drug level | FAERS: 1 | US FAERS | |
| 340 | Antipsychotic drug level above therapeutic | FAERS: 1 | US FAERS | |
| 341 | Antipsychotic drug level increased | FAERS: 1 | US FAERS | |
| 342 | Application site abscess | FAERS: 1 | US FAERS | |
| 343 | Application site warmth | FAERS: 1 | US FAERS | |
| 344 | Arthropod sting | FAERS: 1 | US FAERS | |
| 345 | Atrial Fibrillation | FAERS: 1 | US FAERS | |
| 346 | Automatism | FAERS: 1 | US FAERS | |
| 347 | Belligerence | FAERS: 1 | US FAERS | |
| 348 | Bipolar I disorder | FAERS: 1 | US FAERS | |
| 349 | Blood alcohol increased | FAERS: 1 | US FAERS | |
| 350 | Blood creatinine abnormal | FAERS: 1 | US FAERS | |
| 351 | Blood iron decreased | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 352 | Blood potassium increased | FAERS: 1 | US FAERS | |
| 353 | Blood thyroid stimulating hormone increased | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 354 | Body temperature fluctuation | FAERS: 1 | US FAERS | |
| 355 | Breast tenderness | FAERS: 1 | US FAERS | |
| 356 | Bruxism | FAERS: 1 | US FAERS | |
| 357 | Cardiac Flutter | FAERS: 1 | US FAERS | |
| 358 | Cardiac Hypertrophy | FAERS: 1 | US FAERS | |
| 359 | Cardiac discomfort | FAERS: 1 | US FAERS | |
| 360 | Cataract operation | FAERS: 1 | US FAERS | |
| 361 | Catarrh | FAERS: 1 | US FAERS | |
| 362 | Cerebellar Ataxia | FAERS: 1 | US FAERS | |
| 363 | Cerebral Thrombosis | FAERS: 1 | US FAERS | |
| 364 | Cholecystitis | FAERS: 1 | US FAERS | |
| 365 | Chronic gastritis | FAERS: 1 | US FAERS | |
| 366 | Cogwheel Rigidity | FAERS: 1 | US FAERS | |
| 367 | Cyst | FAERS: 1 | US FAERS | |
| 368 | Cytopenia | FAERS: 1 | US FAERS | |
| 369 | Dental caries | FAERS: 1 | US FAERS | |
| 370 | Depression suicidal | FAERS: 1 | US FAERS | |
| 371 | Dermatomyositis | FAERS: 1 | US FAERS | |
| 372 | Device defective | FAERS: 1 | US FAERS | |
| 373 | Diabetic Ketoacidosis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 374 | Diabetic metabolic decompensation | FAERS: 1 | US FAERS | |
| 375 | Diet refusal | FAERS: 1 | US FAERS | |
| 376 | Disability | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 377 | Dissociative disorder | FAERS: 1 | US FAERS | |
| 378 | Drug clearance decreased | FAERS: 1 | US FAERS | |
| 379 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 380 | Drug diversion | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 381 | Dysentery | FAERS: 1 | US FAERS | |
| 382 | Ear discomfort | FAERS: 1 | US FAERS | |
| 383 | Ectopic Pregnancy | FAERS: 1 | US FAERS | |
| 384 | Ejection Fraction Decreased | FAERS: 1 | US FAERS | |
| 385 | Electrocardiogram abnormal | FAERS: 1 | US FAERS | |
| 386 | Electrocardiogram change | FAERS: 1 | US FAERS | |
| 387 | Electrocardiogram repolarisation abnormality | FAERS: 1 | US FAERS | |
| 388 | Embolism | FAERS: 1 | US FAERS | |
| 389 | Emergency Care | FAERS: 1 | US FAERS | |
| 390 | Eosinophilia | FAERS: 1 | US FAERS | |
| 391 | Erection increased | FAERS: 1 | US FAERS | |
| 392 | Essential Hypertension | FAERS: 1 | US FAERS | |
| 393 | Excessive eye blinking | FAERS: 1 | US FAERS | |
| 394 | Exophthalmos | FAERS: 1 | US FAERS | |
| 395 | Exposure via breast milk | FAERS: 1 | US FAERS | |
| 396 | Extremity contracture | FAERS: 1 | US FAERS | |
| 397 | Eye Infection | FAERS: 1 | US FAERS | |
| 398 | Facial Paresis | FAERS: 1 | US FAERS | |
| 399 | Fat necrosis | FAERS: 1 | US FAERS | |
| 400 | Feeling jittery | FAERS: 1 | US FAERS | |
| 401 | Fibromyalgia | FAERS: 1 | US FAERS | |
| 402 | Flushing | FAERS: 1 | US FAERS | |
| 403 | Freezing phenomenon | FAERS: 1 | US FAERS | |
| 404 | Gastric ulcer | FAERS: 1 | US FAERS | |
| 405 | Gastrointestinal carcinoma | FAERS: 1 | US FAERS | |
| 406 | Gastrointestinal motility disorder | FAERS: 1 | US FAERS | |
| 407 | Gastrooesophageal sphincter insufficiency | FAERS: 1 | US FAERS | |
| 408 | Gender Dysphoria | FAERS: 1 | US FAERS | |
| 409 | Heat illness | FAERS: 1 | US FAERS | |
| 410 | Hemiparesis | FAERS: 1 | US FAERS | |
| 411 | Hepatitis C | FAERS: 1 | US FAERS | |
| 412 | Hepatotoxicity | FAERS: 1 | US FAERS | |
| 413 | Hirsutism | FAERS: 1 | US FAERS | |
| 414 | Homicide | FAERS: 1 | US FAERS | |
| 415 | Hostility | FAERS: 1 | US FAERS | |
| 416 | Hunger | FAERS: 1 | US FAERS | |
| 417 | Hypercapnia | FAERS: 1 | US FAERS | |
| 418 | Hyperthyroidism | FAERS: 1 | US FAERS | |
| 419 | Hypophagia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 420 | Hypopituitarism | FAERS: 1 | US FAERS | |
| 421 | Ileus | FAERS: 1 | US FAERS | |
| 422 | Impaired quality of life | FAERS: 1 | US FAERS | |
| 423 | Inappropriate affect | FAERS: 1 | US FAERS | |
| 424 | Incontinence | FAERS: 1 | US FAERS | |
| 425 | Incorrect drug administration rate | FAERS: 1 | US FAERS | |
| 426 | Incorrect storage of drug | FAERS: 1 | US FAERS | |
| 427 | Injection site discomfort | FAERS: 1 | US FAERS | |
| 428 | Injection site necrosis | FAERS: 1 | US FAERS | |
| 429 | Injection site vesicles | FAERS: 1 | US FAERS | |
| 430 | Injection site warmth | FAERS: 1 | US FAERS | |
| 431 | Intellectual Disability | FAERS: 1 | US FAERS | |
| 432 | Intentional product misuse | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 433 | Intentional product use issue | FAERS: 1 | US FAERS | |
| 434 | Internal injury | FAERS: 1 | US FAERS | |
| 435 | Intestinal Obstruction | FAERS: 1 | US FAERS | |
| 436 | Ketoacidosis | FAERS: 1 | US FAERS | |
| 437 | Laryngospasm | FAERS: 1 | US FAERS | |
| 438 | Leukocytoclastic vasculitis | FAERS: 1 | US FAERS | |
| 439 | Limb discomfort | FAERS: 1 | US FAERS | |
| 440 | Limb injury | FAERS: 1 | US FAERS | |
| 441 | Lipodystrophy acquired | FAERS: 1 | US FAERS | |
| 442 | Locked-In Syndrome | FAERS: 1 | US FAERS | |
| 443 | Macroglossia | FAERS: 1 | US FAERS | |
| 444 | Male genital examination abnormal | FAERS: 1 | US FAERS | |
| 445 | Malignant neoplasm progression | FAERS: 1 | US FAERS | |
| 446 | Mastectomy | FAERS: 1 | US FAERS | |
| 447 | Mastication disorder | FAERS: 1 | US FAERS | |
| 448 | Medical device complication | FAERS: 1 | US FAERS | |
| 449 | Meningitis | FAERS: 1 | US FAERS | |
| 450 | Metrorrhagia | FAERS: 1 | US FAERS | |
| 451 | Musculoskeletal chest pain | FAERS: 1 | US FAERS | |
| 452 | Mutism | FAERS: 1 | US FAERS | |
| 453 | Mycosis Fungoides | FAERS: 1 | US FAERS | |
| 454 | Mydriasis | FAERS: 1 | US FAERS | |
| 455 | Myoclonus | FAERS: 1 | US FAERS | |
| 456 | Myosclerosis | FAERS: 1 | US FAERS | |
| 457 | Myositis | FAERS: 1 | US FAERS | |
| 458 | Nasal mucosal hypertrophy | FAERS: 1 | US FAERS | |
| 459 | Necrosis | FAERS: 1 | US FAERS | |
| 460 | Neuralgia | FAERS: 1 | US FAERS | |
| 461 | Neurodermatitis | FAERS: 1 | US FAERS | |
| 462 | Nodular fasciitis | FAERS: 1 | US FAERS | |
| 463 | Non-cardiac chest pain | FAERS: 1 | US FAERS | |
| 464 | Nuchal Rigidity | FAERS: 1 | US FAERS | |
| 465 | Ocular Hypertension | FAERS: 1 | US FAERS | |
| 466 | Ocular discomfort | FAERS: 1 | US FAERS | |
| 467 | Ocular icterus | FAERS: 1 | US FAERS | |
| 468 | Oncologic complication | FAERS: 1 | US FAERS | |
| 469 | Ophthalmoplegia | FAERS: 1 | US FAERS | |
| 470 | Oropharyngeal spasm | FAERS: 1 | US FAERS | |
| 471 | Performance status decreased | FAERS: 1 | US FAERS | |
| 472 | Pericardial effusion | FAERS: 1 | US FAERS | |
| 473 | Peritonitis | FAERS: 1 | US FAERS | |
| 474 | Persistent depressive disorder | FAERS: 1 | US FAERS | |
| 475 | Photophobia | FAERS: 1 | US FAERS | |
| 476 | Physical assault | FAERS: 1 | US FAERS | |
| 477 | Pleurothotonus | FAERS: 1 | US FAERS | |
| 478 | Pneumonitis | FAERS: 1 | US FAERS | |
| 479 | Poisoning | FAERS: 1 | US FAERS | |
| 480 | Polymyositis | FAERS: 1 | US FAERS | |
| 481 | Posterior reversible encephalopathy syndrome | FAERS: 1 | US FAERS | |
| 482 | Premature Ejaculation | FAERS: 1 | US FAERS | |
| 483 | Pressure of speech | FAERS: 1 | US FAERS | |
| 484 | Product administered at inappropriate site | FAERS: 1 | US FAERS | |
| 485 | Product administered to patient of inappropriate age | FAERS: 1 | US FAERS | |
| 486 | Product packaging issue | FAERS: 1 | US FAERS | |
| 487 | Product prescribing error | FAERS: 1 | US FAERS | |
| 488 | Product residue present | FAERS: 1 | US FAERS | |
| 489 | Product solubility abnormal | FAERS: 1 | US FAERS | |
| 490 | Pseudoparalysis | FAERS: 1 | US FAERS | |
| 491 | Psychogenic seizure | FAERS: 1 | US FAERS | |
| 492 | Pulmonary Infarction | FAERS: 1 | US FAERS | |
| 493 | Pulmonary pain | FAERS: 1 | US FAERS | |
| 494 | Pyomyositis | FAERS: 1 | US FAERS | |
| 495 | Rash erythematous | FAERS: 1 | US FAERS | |
| 496 | Reduced facial expression | FAERS: 1 | US FAERS | |
| 497 | Renal pain | FAERS: 1 | US FAERS | |
| 498 | Respiratory Depression | FAERS: 1 | US FAERS | |
| 499 | Resting Tremor | FAERS: 1 | US FAERS | |
| 500 | Scleroderma | FAERS: 1 | US FAERS | |
| 501 | Semen volume decreased | FAERS: 1 | US FAERS | |
| 502 | Sensation of blood flow | FAERS: 1 | US FAERS | |
| 503 | Septic Shock | FAERS: 1 | US FAERS | |
| 504 | Serotonin Syndrome | FAERS: 1 | US FAERS | |
| 505 | Sexual activity increased | FAERS: 1 | US FAERS | |
| 506 | Shock | FAERS: 1 | US FAERS | |
| 507 | Skin Induration | FAERS: 1 | US FAERS | |
| 508 | Skin tightness | FAERS: 1 | US FAERS | |
| 509 | Slow response to stimuli | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 510 | Snoring | FAERS: 1 | US FAERS | |
| 511 | Soliloquy | FAERS: 1 | US FAERS | |
| 512 | Somatic symptom disorder | FAERS: 1 | US FAERS | |
| 513 | Sopor | FAERS: 1 | US FAERS | |
| 514 | Spermatozoa abnormal | FAERS: 1 | US FAERS | |
| 515 | Starvation | FAERS: 1 | US FAERS | |
| 516 | Supraventricular tachycardia | FAERS: 1 | US FAERS | |
| 517 | Suspected counterfeit product | FAERS: 1 | US FAERS | |
| 518 | Symphysiolysis | FAERS: 1 | US FAERS | |
| 519 | Tachyphrenia | FAERS: 1 | US FAERS | |
| 520 | Tetany | FAERS: 1 | US FAERS | |
| 521 | Therapeutic response unexpected | FAERS: 1 | US FAERS | |
| 522 | Thermal burn | FAERS: 1 | US FAERS | |
| 523 | Thrombophlebitis | FAERS: 1 | US FAERS | |
| 524 | Tongue movement disturbance | FAERS: 1 | US FAERS | |
| 525 | Tongue spasm | FAERS: 1 | US FAERS | |
| 526 | Tooth Loss | FAERS: 1 | US FAERS | |
| 527 | Trisomy 21 | FAERS: 1 | US FAERS | |
| 528 | Uterine Cancer | FAERS: 1 | US FAERS | |
| 529 | VIIth nerve paralysis | FAERS: 1 | US FAERS | |
| 530 | Vaginal Prolapse | FAERS: 1 | US FAERS | |
| 531 | Violence-related symptom | FAERS: 1 | US FAERS | |
| 532 | Vulvovaginal mycotic infection | FAERS: 1 | US FAERS | |
| 533 | Waist circumference increased | FAERS: 1 | US FAERS | |
| 534 | Wolff-Parkinson-White Syndrome | FAERS: 1 | US FAERS | |
| 535 | Wrong dose | FAERS: 1 | US FAERS | |
| 536 | furuncle | FAERS: 1 | US FAERS | |
| 537 | Anuria | Canada Vigilance: 1 | Canada Vigilance | |
| 538 | Basal Ganglia Diseases | 15565299 | CTD | |
| 539 | Blood glucose decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 540 | Cellulitis | Canada Vigilance: 1 | Canada Vigilance | |
| 541 | Chromaturia | Canada Vigilance: 1 | Canada Vigilance | |
| 542 | Drug resistance | Canada Vigilance: 1 | Canada Vigilance | |
| 543 | Dry skin | Canada Vigilance: 1 | Canada Vigilance | |
| 544 | Hyperprolactinemia | 17502783 | CTD | |
| 545 | Mental disorders | 16856516 | CTD | |
| 546 | Paternal exposure during pregnancy | Canada Vigilance: 2 | Canada Vigilance | |
| 547 | Penile size reduced | Canada Vigilance: 1 | Canada Vigilance | |
| 548 | Personality Disorders | 19066856 | CTD | |
| 549 | Productive Cough | Canada Vigilance: 1 | Canada Vigilance | |
| 550 | Stereotypic Movement Disorder | 20662826 | CTD | |
| 551 | Sudden Cardiac Death | Canada Vigilance: 1 | Canada Vigilance | |
| 552 | Underweight | Canada Vigilance: 1 | Canada Vigilance | |
| 553 | Vitamin D Deficiency | Canada Vigilance: 1 | Canada Vigilance | |
| 554 | Weight Gain | 17460786 | CTD |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.